192 related articles for article (PubMed ID: 38390793)
1. Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
Bhatt AS; Vaduganathan M; Claggett BL; Kulac IJ; Anand IS; Desai AS; Fang JC; Hernandez AF; Jhund PS; Kosiborod MN; Sabatine MS; Shah SJ; Vardeny O; McMurray JJV; Solomon SD; Gaziano TA
J Am Heart Assoc; 2024 Mar; 13(5):e032279. PubMed ID: 38390793
[TBL] [Abstract][Full Text] [Related]
2. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
Davis JA; Booth D; McEwan P; Solomon SD; McMurray JJV; de Boer RA; Comin-Colet J; Bachus E; Chen J
Eur J Heart Fail; 2024 Mar; 26(3):664-673. PubMed ID: 38509642
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER.
Peikert A; Vaduganathan M; Claggett BL; Kulac IJ; Foà A; Desai AS; Jhund PS; Carberry J; Lam CSP; Kosiborod MN; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Køber L; Ponikowski P; Sabatine MS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2024 Apr; 26(4):912-924. PubMed ID: 38487939
[TBL] [Abstract][Full Text] [Related]
5. Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
Kim ES; Park SK; Cho DS; Youn JC; Lee HS; Lee HY; Cho HJ; Choi JO; Jeon ES; Lee SE; Kim MS; Kim JJ; Hwang KK; Cho MC; Chae SC; Kang SM; Park JJ; Choi DJ; Yoo BS; Cho JY; Kim KH; Oh BH; Greenberg B; Baek SH
Am J Cardiovasc Drugs; 2024 Mar; 24(2):313-324. PubMed ID: 38413500
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
Reifsnider OS; Tafazzoli A; Linden S; Ishak J; Rakonczai P; Stargardter M; Kuti E
J Am Heart Assoc; 2024 Feb; 13(4):e029042. PubMed ID: 38362909
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS
JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742
[TBL] [Abstract][Full Text] [Related]
10. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
[TBL] [Abstract][Full Text] [Related]
12. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER.
Desai AS; Jhund PS; Claggett BL; Vaduganathan M; Miao ZM; Kondo T; Barkoudah E; Brahimi A; Connolly E; Finn P; Lang NN; Mc Causland FR; McGrath M; Petrie MC; McMurray JJV; Solomon SD
JAMA Cardiol; 2022 Dec; 7(12):1227-1234. PubMed ID: 36189985
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
McEwan P; Darlington O; McMurray JJV; Jhund PS; Docherty KF; Böhm M; Petrie MC; Bergenheim K; Qin L
Eur J Heart Fail; 2020 Nov; 22(11):2147-2156. PubMed ID: 32749733
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China.
Jiang Y; Zheng R; Sang H
Front Pharmacol; 2021; 12():733681. PubMed ID: 34858172
[No Abstract] [Full Text] [Related]
18. Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
Rane A; Nechi RN; Imam M; Zoni CR; Ndikumukiza C; Karaye IM; Yunusa I; Alanzi A
J Manag Care Spec Pharm; 2023 Sep; 29(9):1045-1053. PubMed ID: 37610112
[No Abstract] [Full Text] [Related]
19. A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials.
García-Moll X; Croci F; Solé A; Hartgers-Gubbels ES; Calleja-Hernández MA
Expert Rev Cardiovasc Ther; 2024; 22(1-3):131-139. PubMed ID: 38416135
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial.
Booth D; Davis JA; McEwan P; Solomon SD; McMurray JJV; De Boer RA; Comin-Colet J; Bachus E; Chen J
Eur J Heart Fail; 2023 Aug; 25(8):1386-1395. PubMed ID: 37344985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]